Bendamustine and rituximab in relapsed and refractory hairy cell leukemia

Mauricio Burotto, Maryalice Stetler-Stevenson, Evgeny Arons, Hong Zhou, Wyndham Wilson, Robert J. Kreitman*

*Autor correspondiente de este trabajo

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

63 Citas (Scopus)


Purpose: To determine tolerability and for the first time explore efficacy of bendamustine-rituximab (BR) in multiply relapsed/refractory hairy cell leukemia (HCL), using two different dose levels of bendamustine. Experimental Design: Patients with HCL with ≥ 2 prior therapies requiring treatment received rituximab 375 mg/m2 days 1 and 15 plus bendamustine 70 (n = 6) or 90 (n = 6) mg/m2, days 1 and 2, for six cycles at 4-week intervals. Results: At 70 and 90 mg/m2/dose of bendamustine, overall response rate was 100%, with three (50%) and four (67%) complete remissions (CR) in each respective group. Minimal residual disease (MRD) was absent in 67% and 100% of CRs, respectively. All six without MRD remain in CRat 30 to 35 (median, 31) months of follow-up. Soluble CD22 and CD25 levels decreased with all responses, with median values decreasing from 17.7 and 42 ng/mL at baseline to undetectable and 2 ng/mL after CR, respectively (P < 0.001). Of 12 patients receiving 72 cycles of BR, the most common toxicities were hematologic, including thrombocytopenia (83%), lymphopenia (75%), leukopenia (58%), and neutropenia (42%). Grade III and IV hematologic toxicity included lymphopenia and thrombocytopenia (each 75%), leukopenia (58%), and neutropenia (25%). No significant dose-related differences were detected in response or toxicity. Conclusion: BR has significant activity in HCL. Bendamustine at either 70 or 90 mg/m2/dose was highly effective in multiply relapsed/refractory HCL and could be considered for achieving durable CRs without MRD in patients after failure of standard therapies. As it was not dose-limiting, 90 mg/m 2/dose was chosen for future testing.

Idioma originalInglés
Páginas (desde-hasta)6313-6321
Número de páginas9
PublicaciónClinical Cancer Research
EstadoPublicada - 15 nov. 2013
Publicado de forma externa


Profundice en los temas de investigación de 'Bendamustine and rituximab in relapsed and refractory hairy cell leukemia'. En conjunto forman una huella única.

Citar esto